BiomX Inc. (NYSE: PHGE) announced that NYSE American has accepted the company’s plan to regain compliance with stockholders’ equity listing requirements, providing a pathway for continued listing while management works to address financial deficiencies.

According to the company, NYSE American granted BiomX until September 25, 2027 to cure compliance issues related to stockholders’ equity standards. The company reported a stockholders’ deficit of approximately $1.3 million and has also recorded recurring operating losses.

Acceptance of a compliance plan does not immediately resolve listing concerns, but it allows shares to remain traded on the exchange while corrective actions are implemented. Companies in similar situations are generally subject to periodic review and must continue meeting other listing requirements.

BiomX focuses on developing therapies based on bacteriophage technology, an area of biotechnology research attracting growing scientific interest. However, like many development-stage biotechnology companies, the business continues to face funding challenges and ongoing operating losses associated with research activities.

Maintaining an exchange listing can be important for capital access, institutional investor participation, and overall market visibility. As a result, compliance-related announcements are closely monitored by shareholders.

Despite securing approval of its compliance plan, BiomX shares fell sharply, closing down 24% at $0.54. The decline suggests investors remain concerned about the company’s financial position and the steps required to restore compliance.

Biotechnology companies frequently encounter balance-sheet pressures while advancing clinical programs. The need for additional capital, combined with uncertain development timelines, can create significant volatility in share prices.

Management is expected to pursue measures aimed at strengthening stockholders’ equity and improving financial stability. Potential actions could include capital raising initiatives, operational adjustments, or strategic transactions, although no specific plans were outlined in the announcement.

The company’s ability to meet compliance milestones over the next several years will likely remain an important factor influencing investor confidence. Market participants will also continue monitoring clinical progress and broader financing developments.

For BiomX (NYSE: PHGE), the exchange’s decision provides valuable time to address its financial challenges. Whether the company can successfully execute its remediation strategy while advancing its scientific programs will remain a key focus for investors through 2027.